Ocular melanoma is the most common primary intraocular malignancy in adults and arises from melanocytes within the uveal tract—primarily the choroid, followed by the ciliary body and iris. Clinically, it is distinct from skin melanoma in epidemiology and some molecular drivers, yet it shares overlapping principles of tumor biology such as pigment production, metastatic potential, and progression through acquired genetic alterations. A key public health implication is the high risk of metastasis, particularly to the liver, even when the primary eye tumor is locally controlled.
Epidemiology and risk profile: The incidence varies by ancestry and geographic region, with the highest rates reported in populations of European descent. Risk is strongly associated with lighter skin phenotypes, ocular factors, and age; most cases present in middle adulthood to older age. Although sunlight exposure is a major driver for cutaneous melanoma, the relationship with ocular melanoma is less consistent, suggesting that genetic susceptibility and age-related mutational burden play substantial roles. Known associations include certain hereditary syndromes and abnormalities of pigmentation, including choroidal nevi.
Pathogenesis and molecular mechanisms: Uveal melanoma develops from malignant transformation of uveal melanocytes. Tumor behavior is influenced by driver mutations and chromosomal changes. Common alterations involve genes such as GNAQ and GNA11 (notably in choroidal melanomas), leading to dysregulated signaling pathways that promote proliferation and survival. Additional copy number changes—such as monosomy 3 or other structural rearrangements—correlate with metastatic risk. From a clinical standpoint, these molecular signals underpin modern prognostication models and guide surveillance intensity.
Clinical presentation: Symptoms may be subtle, and diagnosis is often incidental during routine ophthalmic examination. When symptomatic, patients may report blurry vision, a visual field defect, photopsias, or floaters. On exam, a choroidal melanoma may appear as a pigmented or amelanotic elevated choroidal mass. Diagnostic imaging is central: ocular ultrasound helps characterize internal reflectivity and lesion dimensions; optical coherence tomography (OCT) evaluates overlying retina and can show subretinal fluid; fluorescein angiography and indocyanine green angiography assess vascular patterns and lesion activity. In selected cases, MRI of the orbits and systemic staging imaging are used to evaluate extent and rule out metastasis.
Diagnosis and differential: Definitive diagnosis integrates clinical features with imaging. Important differentials include choroidal nevus, hemangioma, metastatic lesions to the eye, and inflammatory pseudotumors. Distinguishing melanoma from nevus is crucial because the metastatic implications are substantially higher for malignant lesions.
Staging and risk stratification: Traditional anatomic staging considers tumor size, location, and evidence of local extraocular extension. However, metastatic potential is largely determined by tumor biology. Molecular prognostic markers and clinicopathologic factors inform risk categorization, including the likelihood of distant metastases. Because microscopic metastatic disease can exist at diagnosis, comprehensive baseline evaluation and planned systemic surveillance are recommended.
Treatment principles: Management aims to achieve local tumor control while preserving ocular function and minimizing treatment morbidity. Options depend on tumor size, location, patient vision, and risk profile. Radiation-based therapies are widely used: plaque brachytherapy delivers targeted radiation, while proton beam therapy and stereotactic approaches offer alternatives, particularly for medium lesions. For select small tumors, observation may be inappropriate if malignant transformation is suspected; instead, definitive treatment is favored. For large tumors or specific circumstances, enucleation (removal of the eye) may be considered to reduce local complications and provide tissue for histopathology and molecular testing.
Systemic therapy and metastatic surveillance: There is currently no universally effective adjuvant systemic therapy that reliably prevents metastasis across all patients. Metastatic ocular melanoma has historically had limited response to conventional chemotherapy, reflecting immune evasion and resistance mechanisms. Immune checkpoint inhibitors and targeted therapies are under investigation, with ongoing research into tumor mutational profile and microenvironmental features. In practice, systemic management often involves clinical trial enrollment when feasible, alongside vigilant surveillance for liver involvement.
Follow-up and supportive care: After treatment, patients require structured follow-up with ophthalmic assessments and systemic monitoring—commonly liver-focused imaging—aligned with risk level. Addressing psychosocial impact is also essential; coping with vision loss risk, uncertainty about metastasis, and treatment side effects can be psychologically burdensome. Multidisciplinary care involving oncology, ophthalmology, radiation oncology, imaging specialists, and supportive services improves adherence and overall outcomes.
Source: [ACureInSight1]
A Cure In Sight: What an incredible morning at the 2026 Lookin’ For A Cure 5K in Jupiter! ☀️👟💙 We welcomed 170 participants and raised $13,223.99 to support ocular melanoma patients! 📸 Race photos are now available and can be downloaded for free:. #breaking
— @ACureInSight1 May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
